Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Not yet recruiting 2Unknown 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 1

Conditions

Pancreatic Neoplasms 8Cholangiocarcinoma 4Stomach Neoplasms 3Small Cell Lung Carcinoma 3Ovarian Neoplasms 3Neuroendocrine Tumors 3Carcinoma, Non-Small-Cell Lung 3Biliary Tract Neoplasms 3Osteosarcoma 2Carcinoma, Neuroendocrine 2Carcinoma, Hepatocellular 2Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Solid Tumor 1Sarcoma 1Refractory Metastatic Digestive System Carcinoma 1Pulmonary Neuroendocrine Tumor 1Pancreatic cancer, adult 1Pancreatic Cancer Metastatic 1Neuroendocrine Tumor Grade 3 1Neoplasms 1Neoplasm Metastasis 1NSCLC 1Locally Advanced Pancreatic Cancer 1Head and Neck Cancers - Salivary Gland 1Gallbladder Neoplasms 1Differentiated Thyroid Cancer 1Colorectal Neoplasms 1Carcinoma 1Breast Neoplasms 1

Interventions

Oxaliplatin 200Capecitabine 116S 1 (combination) 106Fluorouracil 105Docetaxel 100Cisplatin 88Leucovorin 75Paclitaxel 71Irinotecan 68apatinib 43sintilimab 42Drug Therapy 42Surgical Procedures, Operative 37Hyperthermic Intraperitoneal Chemotherapy 34pembrolizumab 32Radiotherapy 31Trastuzumab 30Gastrectomy 23Nivolumab 22Epirubicin 22Tegafur 21Bevacizumab 21XELOX 20titanium silicide 19camrelizumab 19tislelizumab 17Ramucirumab 17Carboplatin 16Neoadjuvant Therapy 15Endoscopic Mucosal Resection 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Stomach Neoplasms × surufatinib × Clear all
NCT06531291 2024-07-31

Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation

RenJi Hospital

Phase 2 Not yet recruiting
80 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms

NCT06447636 2024-06-07

Perioperative Surufatinib Plus Sintilimab Combined With Chemotherapy in Gastric/Gastroesophageal Junction Adenocarcinoma

Fudan University

Phase 2 Not yet recruiting
20 enrolled
Gastrointestinal

Stomach Neoplasms

NCT05527821 2022-09-06

Study of Surufatinib Combined With Sintilimab and SCRT in Advanced Solid Tumors

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 2 Unknown
36 enrolled
GastrointestinalThoracic

Stomach Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡